key: cord-0866064-mw6bws6i
authors: Youhanna, Sonia; Wright, Shane C.; Lauschke, Volker M.
title: Organotypic human ex vivo models for COVID-19 research and drug development
date: 2021-04-27
journal: Curr Opin Pharmacol
DOI: 10.1016/j.coph.2021.04.006
sha: ece284968fd84b1d54eb1ab924541d9d76ea6828
doc_id: 866064
cord_uid: mw6bws6i

Since the discovery of SARS-CoV-2 in late 2019, intense research efforts on an unprecedented scale have focused on the study of viral entry mechanisms and adaptive immunity. While the identification of ACE2 and other co-receptors have elucidated the molecular and structural basis for viral entry, the pathobiological mechanisms of SARS-CoV-2 in human tissues are less understood. The recent advances in bioengineering have opened opportunities for the use of organotypic human tissue models to investigate host-virus interactions and test antiviral drug candidates in a physiological context. While it is too early to accurately quantify the added value of these systems compared to conventional cell systems, it can be assumed that these advanced 3D models contribute towards improved result translation. This mini-review summarizes recent work to study SARS-CoV-2 infection in human 3D tissue models with an emphasis on the pharmacological tools that have been developed to understand and prevent viral entry and replication.

The coronavirus disease 2019 (COVID- 19) pandemic has resulted in an unprecedented shift in research activities aimed at collectively combining efforts to develop treatments for SARS-CoV-2 and minimize its spread in the community. This has led to the uncoordinated use of different cell and tissue models to study SARS-CoV-2 infection and treatment modalities [1] . The choice of model system has important implications in the context of functional pharmacology, where lead compounds encounter a bottleneck in drug discovery at the preclinical or clinical phase due to a lack of therapeutic value. What complicates the matter further is that while COVID-19 is primarily a respiratory disease, it is now clear that it can also result in a multitude of extrapulmonary manifestations, including liver and renal injury, endothelial damage, neurologic symptoms and beta-cell dysfunction [2] .

The expression of SARS-CoV-2 receptors and entry factors has been studied across healthy human tissues [3] , but the effects of infection on host cell molecular signatures are limited to the airway epithelium, lung and intestine, and are mostly based on biopsy samples. To allow for longitudinal profiling, the establishment of an accessible panel of human organotypic 3D tissue models provides a promising tool kit to study the tissue-specific pathobiology of viral infections. Previously, 3D models have been used to study a multitude of enteric infections, including coxsackie B1 virus [4] norovirus [5] , rotavirus [6] and enterohemorrhagic Escherichia coli [7] , hepatitis viruses [8, 9] and respiratory viruses, such as respiratory syncytial virus [10] , influenza virus [11, 12] and parainfluenza virus 3 [13] .

The choice of model system depends on several factors, but perhaps the biggest differences are found when investigating the pharmacology of conventional prophylactics versus vaccines. While prophylactics largely depend on the nature of the selected cell system, vaccines rely on an understanding of the virus itself. In the case of COVID-19, which can progress to affect multiple organs, further consideration should be given to the stage of infection (i.e. initial infection vs. multiorgan failure).

To study the complex pathophysiology of SARS-CoV-2 infection in human tissues, cell lines and animal models have important limitations due to species differences in virus tropism and cell line-specific peculiarities of host cell response. For instance, since their isolation in the late 1960s, African green monkey kidney cells (Vero) have routinely been used as host cells for virus propagation and the testing of antiviral drug candidates. However, Vero cells lack the capacity to produce interferons, which is an important consideration, particularly for the study of interferon susceptible viruses, such as SARS-CoV-2. Such caveats necessitate the use of other emerging culture models, such as stem cell-derived organoids and 3D primary tissue models, that may better represent the pathophysiology of infection and increase the fidelity of result translation (Table 1) . For methodological details, as well as critical discussions of advantages and limitations of these culture systems, we refer the interested reader to recent comprehensive reviews [14] [15] [16] [17] .

J o u r n a l P r e -p r o o f Patients with severe COVID-19 can develop acute respiratory distress syndrome (ARDS) characterized by respiratory failure with hypoxemia and acute bilateral pulmonary infiltrates and histopathologic patterns of diffuse alveolar damage and pulmonary microthrombi [18] . Several distal lung epithelial models have been developed that can be infected with SARS-CoV-2 and allow to study viral effects in the distal gas-exchange region of the lungs (Fig. 1a) .

Human primary alveolar organoids have been generated from cells isolated from normal human distal lung tissue co-cultured with MRC-5 human lung fibroblasts [19] .

These organoids were susceptible to SARS-CoV-2 infection and showed robust induction of host response genes including various cytokines, as well as cell autonomous and non-cell autonomous apoptosis, indicative of alveolar injury. At physiological concentrations, remdesivir significantly reduced viral load whereas no effects were observed for hydroxychloroquine.

Human alveolar type II (AT2) cells derived from primary human lung tissue have also been used to investigate the host cell response to SARS-CoV-2 infection in long-term 3D culture [20] . These studies revealed rapid viral replication within a few days post infection paralleled by a strong induction of interferon response gene signatures, indicative of a robust endogenous innate immune response. Furthermore, single cell sequencing showed that while uninfected AT2 cells were relatively homogeneous, SARS-CoV-2 infection resulted in the subdivision of cells into distinct clusters, of which some were characterized by a loss of AT2 identity and compromised alveolar function. Distal lung organoids have also been generated from adult AT2 or keratin 5positive (KRT5+) basal cells [21] . Alveolar organoids differentiated into alveolar type J o u r n a l P r e -p r o o f I (AT1) cells while basal cell organoids became luminal lined with differentiated club and ciliated cells within bronchiolar structures. Importantly, distal lung organoids with apical-out polarity were susceptible to infection and club cells were identified as a novel SARS-CoV-2 target population.

Lung organoids generated by differentiation of primary stem cells derived from tissue sections enabled the modeling of both distal and proximal lung epithelium [22] .

Notably, proximal epithelial cells were more permissive to SARS-CoV-2 infection whereas distal epithelial cells showed increased host cell immune response, highlighting the importance of spatially refined tissue modeling.

Alternatively, human pluripotent stem cells (hPSCs) can be used to generate organoids that recapitulate the cellular complexity of the human distal lung, including AT1 and AT2 cells, stromal cells, pulmonary neuroendocrine cells, as well as airway epithelial cells [23] . Notably, this model allowed for sufficient throughput to screen >1,200 FDA-approved drugs for their ability to inhibit SARS-CoV-2 entry and the authors identified candidate molecules, including imatinib and chloroquine, which inhibited infectivity at subtoxic concentrations. hPSC-derived AT2 cells can furthermore be cultivated as monolayers with apical-basal polarization and barrier integrity on filters in air-liquid interface (ALI) cultures [24] . The presence of virus particles in the vicinity of lamellar bodies suggests that secretion of lung surfactant may be dysregulated by SARS-CoV-2 infection. As in cultures from primary cells, infection increased inflammatory signaling and loss of mature alveolar phenotypes. It is, however, important to note that these culture models lacked immune cell components.

To overcome this limitation, lung and macrophage co-culture systems were developed based on directed differentiation of hPSCs [25] . Importantly, in this model both M1

and M2 macrophages inhibited SARS-CoV-2 infection, but only M1 macrophages increased the production of inflammatory cytokines that facilitated lung cell injury.

Inhibition of viral entry improved M2-mediated viral clearance and resulted in significant protection of lung cells, suggesting that blockade of viral entry or stimulation of M2 macrophages are potential strategies for therapeutic intervention..

CoV-2 infection of pulmonary tissues. In particular, human primary models faithfully recapitulate the molecular and cellular phenotypes of distal and proximal lung epithelium. However, they lack the ability to be stably propagated and are consequently more suitable for mechanistic studies or target validations rather than large scale screens. A major drawback of most current models remains the relatively low cellular complexity, particularly the absence of immune cells, which impairs our understanding of the pathophysiological mechanisms of SARS-CoV-2 infection of pulmonary tissues.

There is considerable interest in organotypic liver models to study virus-liver cell interactions, as well as the pharmacokinetics and toxicity of candidate drugs. This is reinforced by the observation that liver injury has been detected in up to 60% of J o u r n a l P r e -p r o o f severely ill COVID-19 patients [26] , suggesting that liver models could be useful to study extra-pulmonary disease biology ex vivo.

Hepatic effects of SARS-CoV-2 have been studied in stem cell-derived organoids and in organotypic 3D cultures of mature human liver cells. In stem cell-derived liver organoids, SARS-CoV-2 infection could be detected in albumin-positive hepatocytelike cells [27] , as well as in cholangiocytes in human liver ductal organoids based on bile duct-derived progenitor cultures [28] . Interestingly, in the latter, the authors demonstrated that infection impaired the barrier and bile acid transporting functions of cholangiocytes by modulating the expression of tight junction and bile acid transport genes, thus providing a possible link between SARS-CoV-2 and cholestatic liver injury (Fig. 1b) .

Using a well-established primary human hepatocyte (PHH) 3D spheroid model in which liver cells retain their transcriptomic, proteomic and metabolomic configuration [29] [30] [31] , it was shown that mature human hepatocytes are permissive to SARS-CoV-2 infection despite expressing only low levels of ACE2 [32] .

Interestingly, exposure to pro-inflammatory cytokines, particularly class I interferons, resulted in the induction of ACE2 expression and increased liver cell infectivity [33] .

However, whether the full-length functional or truncated non-functional ACE2 isoform [34, 35] becomes induced in human liver remains to be determined. SARS-CoV-2 infection was moreover found to modulate the host cell response of hepatocytes to inflammatory signaling, specifically altering the expression of coagulation factors and genes involved in platelet activation, which might at least in part explain the coagulation defects observed in COVID-19 patients [33] .

The development of a model that recapitulates the pathophysiology of SARS-CoV-2 infection ex vivo opened the possibility to test candidate molecules for COVID-19 drug repurposing. Baricitinib, an oral inhibitor of JAK/STAT signaling approved for the treatment of rheumatoid arthritis, had been suggested by artificial intelligence (AI)-based knowledge graphs as a candidate therapy for COVID-19 by virtue of inhibiting both excessive cytokine signaling and numb-associated kinases that regulate receptor-mediated endocytosis and viral entry at nanomolar levels [36] .

Importantly, baricitinib significantly reversed virus-induced host cell transcriptomic alterations and reduced infectivity, as well as viral load in 3D liver spheroids at therapeutically relevant concentrations (Fig. 1c-e) . More importantly and in alignment with these ex vivo findings, baricitinb significantly reduced mortality in observational trials of elderly patients in Italy and Spain [33] . The promising clinical effects have since been corroborated by a large randomized controlled trial [37] and have resulted in the FDA emergency use authorization (EUA) of baricitinib for COVID-19.

The manifestation of gastrointestinal (GI) symptoms in a subset of SARS-CoV-2 patients [38, 39] and the high expression level of ACE2 in enterocytes [40] have fueled studies into the pathobiology of SARS-CoV-2 in human intestinal tissues. In contrast to lung and liver, ex vivo studies of SARS-CoV-2 infection of intestinal cells have only been presented in stem cell-derived organoid cultures. In small intestinal organoids derived from primary gut epithelial stem cells, SARS-CoV-2 productively infected the enterocyte lineage (Fig. 1f) , whereas enteroendocrine cells and Goblet J o u r n a l P r e -p r o o f cells were not infected [41] . Infections of ACE2-positive enterocytes were promoted by the mucosa-specific serine proteases TMPRSS2 and TMPRSS4 [42] . Interestingly, TMPRSS2 is expressed on Goblet cells, which are themselves resistant to infection, but promotes infection of neighboring enterocytes in trans. Infectious viral particles were detected in stool samples of a patient with diarrheal COVID-19 and viral replication was found to be higher in human colonoids compared to enteroids [43] .

Infection, active replication and viral spread of SARS-CoV-2 also occurred in intestinal organoids derived from hPSC that recapitulated the cellular heterogeneity of the human intestinal lining (Fig. 1g ). In this model the authors observed infection of enterocytes as well as Paneth cells, suggesting potential disruption of hormonal secretion and perturbed local immune defense [44] . The model was successfully used to confirm the anti-viral effects of remdesivir (Fig. 1h ) and the peptidic pancoronavirus fusion inhibitor EK1, but not of the putative TMPRSS2 inhibitor famotidine. In addition, following a high-throughput screen of FDA-approved drugs for antiviral action, imatinib, mycophenolic acid and quinacrine dihydrochloride were confirmed to inhibit SARS-CoV-2 infectivity in hPSC-derived colonic organoids [23] . In short, these results suggest that both primary gut stem cell-and iPSC-derived organoids provide suitable tools to study SARS-CoV-2 cellular tropism and infection biology and validate antiviral drug effects.

Acute kidney injury constitutes a common complication in severely ill COVID-19 patients, occurring in 0.5-7% of cases and in 2.9-23% of ICU patients [45] . The J o u r n a l P r e -p r o o f SARS-CoV-2 entry factors ACE2 and TMPRSS2 are expressed in podocytes and proximal tubule cells, suggesting that these are the primary target cell types. Notably, upon ex vivo culture, ACE2 expression was twice as high in 3D proximal tubule organoids compared to conventional 2D culture, suggesting that 3D cultured cells might be more readily infectable in organotypic culture configurations [46] .

Infectivity with SARS-CoV-2 was also modeled using hPSC-derived kidney organoids that featured clear tubular structures and podocyte-like cells (Fig. 1i) with molecular phenotypes resembling second-trimester human fetal kidneys [47, 48] .

Importantly, viral entry in kidney organoids could be blocked dose-dependently by human, but not mouse soluble recombinant ACE2 [48] . Notably, the effect of human soluble recombinant ACE2 was additive with the intracellular viral replication inhibitor remdesivir, suggesting that combinatorial therapies of agents with mechanistically distinct targets might provide promising strategies for COVID-19 [49] . investments into human tissue engineering, as well as initiatives to improve the benchmarking, standardization and accessibility to such models thus seem warranted to increase the preparedness for current and future public health emergencies.

VML is CEO and shareholder of HepaPredict AB and co-founder and shareholder of PersoMedix AB. In addition, VML discloses consultancy work for Enginzyme AB. Host cell and macrophages from the same hPSC lines avoiding concern of histocompatibility.

Cultures cannot be propagated limiting scalability (preprint).

[11]

Liver hPSC Hepatocyte-like cells

The study also investigated the viral tropism in other stem cell-derived tissues.

Lack of nonparenchymal cells; immature liver phenotypes. [27] J o u r n a l P r e -p r o o f models.

Bile duct-derived progenitor Cholangiocytes Allow for the study of SARS-CoV-2 specifically in cholangiocytes.

Underrepresentation of liver cell complexity.

[28]

Primary human hepatocytes and non-parenchymal cells Hepatocytes Cells retain their mature phenotype on transcriptomic, proteomic and metabolomic level for many weeks; highthroughput compatible.

Use of limited primary material.

[ [29] [30] [31] [32] [33] Intestine 

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

Extrapulmonary manifestations of COVID-19

A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors

Human Gut-On-A-Chip Supports Polarized Infection of Coxsackie B1 Virus In Vitro

Replication of human noroviruses in stem cell-derived human enteroids

Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology

Enterohemorrhagic Escherichia coli reduce mucus and intermicrovillar bridges in human stem cellderived colonoids

Primary Human Hepatocytes in Spheroid Formation to Study Hepatitis C Infection

3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection

A three-dimensional model of human lung development and disease from pluripotent stem cells

Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures

Differentiated human airway organoids to assess infectivity of emerging influenza virus

Authentic Modeling of Human Respiratory Virus Infection in Human Pluripotent Stem Cell-Derived Lung Organoids

Human Pulmonary 3D Models For Translational Research

3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications

Organotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and Toxicity

A bioengineering perspective on modelling the intestinal epithelial physiology in vitro

Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2

Progenitor identification and SARS-CoV-2 infection in human distal lung organoids

Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Modeling COVID-19 with human pluripotent stem cell-derived cells reveals synergistic effects of antiinflammatory macrophages with ACE2 inhibition against SARS-CoV-2

Liver injury in COVID-19: management and challenges

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids

Characterization of primary human hepatocyte spheroids as a model system for druginduced liver injury, liver function and disease

Ingelman-Sundberg M: Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury

Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

:eabe4724. ** Using primary human liver microtissues, the authors show that excessive inflammation induces ACE2 hyperexpression and causes increased infectivity, which could be prevented using the JAK/STAT inhibitor baricitinib. The beneficial effects of baricitinib were

Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option

A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

SARS-CoV-2 productively infects human gut enterocytes

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Infection of bat and human intestinal organoids by SARS-CoV-2

Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell-Derived Intestinal Organoids. Cellular and Molecular Gastroenterology and Hepatology 2020, 382:727. ** Using iPS-derived intestinal organoids, the authors identify remdesivir and EK1 as promising candidate drugs to inhibit viral replication

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Long Term Culture of Human Kidney Proximal Tubule Epithelial Cells Maintains Lineage Functions and Serves as an Ex vivo Model for Coronavirus Associated Kidney Injury

Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Molecular Medicine 2020:e13426. ** This study demonstrates the synergistic effects of mechanistically orthogonal drugs and demonstrate the mechanisms underlying remdesivir toxicity

Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche

Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells